127 related articles for article (PubMed ID: 2584356)
1. Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus.
Eto M; Watanabe K; Sato T; Makino I
J Clin Endocrinol Metab; 1989 Dec; 69(6):1207-12. PubMed ID: 2584356
[TBL] [Abstract][Full Text] [Related]
2. Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes.
Saito M; Eto M; Kaku K
Metabolism; 2002 Aug; 51(8):964-9. PubMed ID: 12145767
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis.
Huang Y; Schwendner SW; Rall SC; Sanan DA; Mahley RW
J Biol Chem; 1997 Sep; 272(36):22685-94. PubMed ID: 9312550
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E phenotype frequency in type II diabetic patients with different forms of hyperlipoproteinemia.
Parhofer KG; Richter WO; Schwandt P
Horm Metab Res; 1990 Nov; 22(11):589-94. PubMed ID: 2272605
[TBL] [Abstract][Full Text] [Related]
5. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
Huang Y; Rall SC; Mahley RW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects.
Cohn JS; Tremblay M; Amiot M; Bouthillier D; Roy M; Genest J; Davignon J
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):149-59. PubMed ID: 8548416
[TBL] [Abstract][Full Text] [Related]
8. Type III hyperlipoproteinema with apolipoprotein E2/2 genotype in Japan.
Eto M; Saito M; Nakata H; Iwashima Y; Watanabe K; Ikoda A; Kaku K
Clin Genet; 2002 Jun; 61(6):416-22. PubMed ID: 12121348
[TBL] [Abstract][Full Text] [Related]
9. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
de Beer F; Stalenhoef AF; Hoogerbrugge N; Kastelein JJ; Gevers Leuven JA; van Duijn CM; Havekes LM; Smelt AH
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):294-9. PubMed ID: 11834531
[TBL] [Abstract][Full Text] [Related]
10. [Familial type III hyperlipoproteinemia].
Eto M; Saito M
Nihon Rinsho; 2013 Sep; 71(9):1590-4. PubMed ID: 24205719
[TBL] [Abstract][Full Text] [Related]
11. Increased frequency of apolipoprotein epsilon 4 allele in type II diabetes with hypercholesterolemia.
Eto M; Watanabe K; Iwashima Y; Morikawa A; Chonan N; Oshima E; Sekiguchi M; Ishii K
Diabetes; 1987 Nov; 36(11):1301-6. PubMed ID: 3666320
[TBL] [Abstract][Full Text] [Related]
12. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance.
de Villiers WJ; van der Westhuyzen DR; Coetzee GA; Henderson HE; Marais AD
Arterioscler Thromb Vasc Biol; 1997 May; 17(5):865-72. PubMed ID: 9157949
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E polymorphism and hyperlipoproteinemia in obesity.
Eto M; Watanabe K; Ishii K
Int J Obes; 1989; 13(4):433-40. PubMed ID: 2793298
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus.
Horita K; Eto M; Makino I
Atherosclerosis; 1994 Jun; 107(2):203-11. PubMed ID: 7980694
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia.
Evans D; Seedorf U; Beil FU
Clin Genet; 2005 Oct; 68(4):369-72. PubMed ID: 16143024
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E allele frequencies in non-insulin-dependent diabetes mellitus with hypertriglyceridemia (type IIb, III, IV, and V hyperlipoproteinemia).
Eto M; Watanabe K; Makino I; Ishii K
Metabolism; 1991 Aug; 40(8):776-80. PubMed ID: 1861626
[TBL] [Abstract][Full Text] [Related]
18. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2.
Breslow JL; Zannis VI; SanGiacomo TR; Third JL; Tracy T; Glueck CJ
J Lipid Res; 1982 Nov; 23(8):1224-35. PubMed ID: 7175379
[TBL] [Abstract][Full Text] [Related]
19. [The relationship of Apo E2 and renal insufficiency lipid levels in NIDDM].
Xiang G; Xia B; He Y
Zhonghua Yi Xue Za Zhi; 1999 May; 79(5):339-41. PubMed ID: 11715472
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
Lin HP; Kao JT
Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
